Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sandoz Group Ltd ( (CH:SDZ) ) has issued an update.
Sandoz reported strong financial results for the first half of 2025, with net sales rising by 4% at constant currencies, driven by a 12% increase in biosimilars sales. The company is strategically investing in biosimilar production capabilities, including a new facility in Slovenia and a proposed acquisition in France, to capitalize on the growing biosimilar market. These developments are expected to enhance Sandoz’s market position and offer long-term value to stakeholders.
The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF50.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.
More about Sandoz Group Ltd
Sandoz Group Ltd is a global leader in the pharmaceutical industry, specializing in generic and biosimilar medicines. The company focuses on providing affordable healthcare solutions and has a significant presence in Europe, North America, and international markets.
Average Trading Volume: 954,834
Technical Sentiment Signal: Buy
Current Market Cap: CHF20.12B
For a thorough assessment of SDZ stock, go to TipRanks’ Stock Analysis page.